ABSTRACT
Spitz nevi of special sites, such as the ear, appear rarely and pose a challenge with worrisome clinical, dermoscopic, or histopathological features. Our aim was to evaluate the morphological findings of a series of Spitz nevi of the ear in order to obtain more knowledge about their clinical-dermoscopic patterns. Of a total of six cases, three main dermoscopic structures were found: pseudonetwork, structureless areas, and cobblestone pattern. Our preliminary findings suggest that dermoscopy may be helpful in improving the diagnostic accuracy of Spitz nevus of the ear and minimize surgery in a sensitive location.
Subject(s)
Nevus, Epithelioid and Spindle Cell , Skin Neoplasms , Child , Dermoscopy , Diagnosis, Differential , Humans , Nevus, Epithelioid and Spindle Cell/diagnosis , Skin Neoplasms/diagnosisABSTRACT
Pityriasis rosea (PR) is an exanthematous disease whose etiology is related to reactivation of herpes human herpesviruses 6 (HHV-6) and 7 (HHV-7). We observed two cases of PR arising during omalizumab therapy for chronic spontaneous urticaria (CSU). Here we report for the first time PR occurring during omalizumab treatment. After PR diagnosis, viral serology was performed. Data in literature about omalizumab mechanism of action, PR and HHV-6/7 infection were analyzed in order to identify possible correlations. In both our cases IgM against HHV-6 and HHV-7 were negative. The first patient presented altered IgG titers for both viruses (1:160 and 1:80, respectively) while only HHV-6 IgG (1:320) were detected in the second patient. From data in literature, we consider it presumable that apoptotic immune cells due to omalizumab immunomodulation could release viral proteins produced from integrated DNA. This could elicit cutaneous cross-reactivity and PR onset. In conclusion, we think there is a link between omalizumab therapy and PR occurring in patients with CSU. Our case history is too small to draw firm conclusions. Data collection of similar cases could be helpful to improve our knowledge.
Subject(s)
Anti-Allergic Agents , Chronic Urticaria , Herpesvirus 6, Human , Herpesvirus 7, Human , Pityriasis Rosea , Urticaria , Anti-Allergic Agents/therapeutic use , Chronic Disease , Humans , Omalizumab/adverse effects , Pityriasis Rosea/chemically induced , Pityriasis Rosea/diagnosis , Pityriasis Rosea/drug therapy , Urticaria/chemically induced , Urticaria/diagnosis , Urticaria/drug therapyABSTRACT
Omalizumab is a monoclonal antibody, targeting Fc receptor of IgE, approved for the treatment of allergic asthma and chronic spontaneous urticaria. Its utility in atopic dermatitis appears controversial from data in literature since the molecule is well tolerated but it seems less effective than other medications used in adult patients (eg, Dupilumab). At present, the use of Dupilumab is not approved in pediatric patients therefore there are no second level treatments available in this age group. Here we report two clinical cases of patients (15 and 16 years old) suffering from both atopic dermatitis and asthma, treated with Omalizumab. Our experience suggests that atopic eczema of young patients with allergic comorbidities can benefit from asthma treatment with Omalizumab observing improvement on both conditions.
Subject(s)
Asthma , Dermatitis, Atopic , Adolescent , Adult , Antibodies, Monoclonal , Antibodies, Monoclonal, Humanized , Asthma/diagnosis , Asthma/drug therapy , Child , Dermatitis, Atopic/diagnosis , Dermatitis, Atopic/drug therapy , Humans , Omalizumab/adverse effectsABSTRACT
Follicular mucinosis (FM) is a rare inflammatory disorder histologically characterized by mucin deposition in the follicular epithelium. There is no standard therapy for FM and several treatments have been described in the literature. We present the case of a 59 year-old female affected by a recalcitrant FM with diffuse scalp alopecia, in which complete clinical remission was achieved after a combination of topical tacalcitol and photodynamic therapy.